BofA analyst Tazeen Ahmad downgraded Prothena (PRTA) to Underperform from Neutral with a price target of $4, down from $22.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- AMD, Block upgraded: Wall Street’s top analyst calls
- Prothena downgraded to Neutral from Overweight at Cantor Fitzgerald
- Prothena’s Hold Rating: Clinical Trial Challenges and Financial Pressures
- Prothena price target lowered to $81 from $110 at Piper Sandler
- Prothena’s Strategic Shift and Promising Alzheimer’s Pipeline Drive Buy Rating